...
首页> 外文期刊>Business week >Major Surgery At Sanofi
【24h】

Major Surgery At Sanofi

机译:赛诺菲的大手术

获取原文
获取原文并翻译 | 示例
           

摘要

The mood was grim at sanofi- aventis when Chris Viehbacher became CEO a year ago. U.S. regulators had rejected the French drugmaker's heralded obesity pill, Acomplia. Sanofi had failed in its legal bid to block generic copies of Plavix, a blood thinner with annual sales of nearly $4 billion. It faced patent expirations on some of its other best-selling drugs, and its labs weren't creating products fast enough to make up for revenues that would be lost to generics.
机译:一年前Chris Viehbacher出任首席执行官时,赛诺菲万提斯的情绪令人沮丧。美国监管机构拒绝了这家法国制药商宣布的肥胖药Acomplia。赛诺菲未能通过法律手段阻止普立维的仿制药生产。普立维是一种血液稀释剂,年销售额近40亿美元。它在其他一些最畅销的药物上面临专利期满,并且其实验室的产品开发速度不足以弥补仿制药可能损失的收入。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号